123 related articles for article (PubMed ID: 20734716)
21. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
22. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
Sin JI
Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
[TBL] [Abstract][Full Text] [Related]
23. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
24. An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus.
Ge FF; Qiu YF; Yang YW; Chen PY
Arch Virol; 2007 Jan; 152(1):125-35. PubMed ID: 16862385
[TBL] [Abstract][Full Text] [Related]
25. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
[TBL] [Abstract][Full Text] [Related]
26. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
27. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
28. Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects.
Zong J; Peng Q; Wang Q; Zhang T; Fan D; Xu X
Oncol Rep; 2009 Oct; 22(4):953-61. PubMed ID: 19724878
[TBL] [Abstract][Full Text] [Related]
29. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice.
Li YL; Liu J; Liu JN; Zhang J
Vaccine; 2011 Aug; 29(35):5959-62. PubMed ID: 21722685
[TBL] [Abstract][Full Text] [Related]
30. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
32. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
33. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
34. [Construction of recombinant vaccinia virus expressing HPV18E7E6 fusion proteins and detection of its immunogenicity in mice].
Zhao L; Ren J; Feng J; Gao J; Zhang H; Tian HW; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):189-91. PubMed ID: 19031699
[TBL] [Abstract][Full Text] [Related]
35. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.
Yan J; Harris K; Khan AS; Draghia-Akli R; Sewell D; Weiner DB
Vaccine; 2008 Sep; 26(40):5210-5. PubMed ID: 18455277
[TBL] [Abstract][Full Text] [Related]
36. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
Li H; Ou X; Xiong J
Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
Sharma C; Dey B; Wahiduzzaman M; Singh N
Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
39. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
40. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
